Unlocking the Potential of DEPDC7: A novel 58.3 KDA protein as a drug target or biomarker

Target Name: DEPDC7

NCBI ID: G91614

DEPDC7

Unlocking the Potential of DEPDC7: A novel 58.3 KDA protein as a drug target or biomarker

Abstract:

DEPDC7, a novel 58.3 KDA protein, has been identified as a potential drug target and biomarker for various diseases. This protein plays a crucial role in various cellular processes, including cell signaling, DNA replication, and apoptosis. In this article, we will explore the DEPDC7 protein, its functions, and its potential as a drug target or biomarker.

Introduction:

The protein encoded by the DEPDC7 gene is a 58.3 kilodalton (KDA) protein that is involved in various cellular processes. It is a member of the Kinesin-67 family, which is known for their role in intracellular transport and cell signaling. DEPDC7 has been shown to play a crucial role in regulating cell proliferation, apoptosis, and DNA replication.

Properties and Functions:

DEPDC7 is a 58.3 KDA protein that is composed of 252 amino acid residues. It has a calculated pI of 9.97 and a predicted localization in the cytoplasm. DEPDC7 is expressed in various tissues and cells, including brain, heart, and cancer cells. It is also a good predictor of cancer outcomes, as low expression levels of DEPDC7 are associated with poor prognosis.

One of the most significant functions of DEPDC7 is its role in cell signaling. It is involved in the regulation of several signaling pathways, including the cell cycle, apoptosis, and DNA replication. DEPDC7 has been shown to play a negative role in cell proliferation and has been used as a potential drug target for various diseases.

In addition to its role in cell signaling, DEPDC7 is also involved in the regulation of apoptosis. It has been shown to play a crucial role in the regulation of apoptosis, as well as the determination of cell fate. DEPDC7 has been shown to interact with several apoptosis-related proteins, including Bcl-2 and p53. These interactions may regulate the regulation of apoptosis and its downstream events.

Furthermore, DEPDC7 is also involved in the regulation of DNA replication. It has been shown to play a critical role in the regulation of DNA replication, as well as the checkpoint mechanism. DEPDC7 has been shown to interact with several DNA replication-related proteins, including DnaC and DnaG. These interactions may regulate the regulation of DNA replication and its downstream events.

Potential as a Drug Target:

The potential of DEPDC7 as a drug target is high due to its various functions in cell signaling, apoptosis, and DNA replication. One of the most promising strategies for targeting DEPDC7 is the use of small molecules. Many small molecules have been shown to interact with DEPDC7 and have the potential to be drug candidates.

One of the most promising small molecules is a compound called R1-249. R1-249 is a potent inhibitor of DEPDC7, with a binding constant (Ki) of 8.4 nM. R1-249 has been shown to inhibit the activity of several DEPDC7- interactive proteins, including the protein kinase ALC/P21. Furthermore, it has been shown to inhibit the growth of several cancer cell lines, including the human breast cancer cell line (MCF-7).

Another promising small molecule is a compound called TK-156. TK-156 is an inhibitor of the protein tyrosine phosphatase, which is a negative regulator of DEPDC7. TK-156 has been shown to inhibit the activity of several DEPDC7-interactive proteins, including the protein tyrosine phosphatase 2 (PTP2).

Another approach to targeting DEPDC7 is the use of antibodies. Antibodies have been shown to be effective in targeting DEPDC7 and can be used

Protein Name: DEP Domain Containing 7

The "DEPDC7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEPDC7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets